KR20240055051A - 백신 생성을 위한 생물학적으로 생성된 핵산 - Google Patents

백신 생성을 위한 생물학적으로 생성된 핵산 Download PDF

Info

Publication number
KR20240055051A
KR20240055051A KR1020247010899A KR20247010899A KR20240055051A KR 20240055051 A KR20240055051 A KR 20240055051A KR 1020247010899 A KR1020247010899 A KR 1020247010899A KR 20247010899 A KR20247010899 A KR 20247010899A KR 20240055051 A KR20240055051 A KR 20240055051A
Authority
KR
South Korea
Prior art keywords
acid sequence
nucleic acid
amino acid
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247010899A
Other languages
English (en)
Korean (ko)
Inventor
엔야 타타나 키퍼
토마스 클림카이트
크리스티안 미텔홀저
파비안 오테
Original Assignee
유니버시타트 바셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시타트 바셀 filed Critical 유니버시타트 바셀
Publication of KR20240055051A publication Critical patent/KR20240055051A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247010899A 2021-09-09 2022-09-09 백신 생성을 위한 생물학적으로 생성된 핵산 Pending KR20240055051A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21195643 2021-09-09
EP21195643.8 2021-09-09
EP22179777 2022-06-19
EP22179777.2 2022-06-19
PCT/EP2022/075140 WO2023036947A1 (en) 2021-09-09 2022-09-09 Biologically produced nucleic acid for vaccine production

Publications (1)

Publication Number Publication Date
KR20240055051A true KR20240055051A (ko) 2024-04-26

Family

ID=83558295

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247010899A Pending KR20240055051A (ko) 2021-09-09 2022-09-09 백신 생성을 위한 생물학적으로 생성된 핵산

Country Status (9)

Country Link
US (1) US20250188127A1 (https=)
EP (1) EP4398935A1 (https=)
JP (1) JP2024533378A (https=)
KR (1) KR20240055051A (https=)
AU (1) AU2022341555A1 (https=)
CA (1) CA3224963A1 (https=)
IL (1) IL310010A (https=)
MX (1) MX2024002259A (https=)
WO (1) WO2023036947A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543046A (ja) * 2019-07-30 2022-10-07 バーンダリ・インコーポレイテッド ウイルス様粒子ワクチン

Also Published As

Publication number Publication date
JP2024533378A (ja) 2024-09-12
AU2022341555A1 (en) 2024-01-18
WO2023036947A1 (en) 2023-03-16
IL310010A (en) 2024-03-01
EP4398935A1 (en) 2024-07-17
MX2024002259A (es) 2024-03-06
AU2022341555A9 (en) 2024-01-25
CA3224963A1 (en) 2023-03-16
US20250188127A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
Olspert et al. Transcriptional slippage in the positive‐sense RNA virus family Potyviridae
CN111744000B (zh) 免疫抑制功能降低的口蹄疫重组病毒及其制备方法与应用
EP3158060B1 (en) Method for rapid generation of an infectious rna virus
CN110904055B (zh) 猪繁殖与呼吸综合征病毒重组疫苗株prrsv-sp及其制备方法与应用
Suhardiman et al. Generation of porcine reproductive and respiratory syndrome virus by in vitro assembly of viral genomic cDNA fragments
CN113736799B (zh) 山羊副流感病毒3型感染性cDNA克隆构建方法及其应用
KR20240055051A (ko) 백신 생성을 위한 생물학적으로 생성된 핵산
US20080131459A1 (en) Full-Length Infectious Cdna Clone for Porcine Reproductive and Respiratory Syndrome Virus(Prrsv) and Uses Thereof
CN119345361B (zh) Rsad1基因为靶点在筛选抑制小核糖核酸病毒科病毒感染药物中的应用
AU2021231238A1 (en) Fully synthetic, long-chain nucleic acid for vaccine production to protect against coronaviruses
CN118076383A (zh) 用于疫苗生产的生物学方法产生的核酸
CN117286178A (zh) 一种双组份病毒载体的简化构建方法及其相关应用
AU736586B2 (en) An infectious clone for human parainfluenza virus type 3
US20240066116A1 (en) Fully synthetic, long-chain nucleic acid for vaccine production to protect against coronaviruses
Yun et al. Bacterial artificial chromosomes: A functional genomics tool for the study of positive-strand RNA viruses
CN118620850B (zh) 一种禽传染性支气管炎病毒弱毒株的制备及其应用
EP3897675A1 (en) Compositions and methods for airway tissue regeneration
CN116004551B (zh) 一种调节mhc-ii类反式激活因子ciita基因的猪繁殖与呼吸综合征病毒活疫苗的构建及其应用
Eriksson et al. Efficient transduction of dendritic cells using coronavirus-based vectors
CN121022762A (zh) 一种稳定表达猪传染性胃肠炎病毒核衣壳蛋白的llc-pk1细胞系及其构建方法和应用
CN117736276A (zh) 肠道病毒71型vp1蛋白高保守位点突变致流产株感染性克隆及其构建方法和应用
CN120818539A (zh) 黄病毒的复制依赖的rna重组实验系统的建立和应用
Archambault et al. The intraleader AUG nucleotide sequence context is important for equine arteritis virus replication
WO2021175960A1 (en) Fully synthetic, long-chain nucleic acid for vaccine production to protect against coronaviruses

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000